Home › Research › Biomarkers
Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie
Poli G, Corda E, Lucchini B, Puricelli M, Martino PA, Dall'ara P, Villetti G, Bareggi SR et al.. Prion, 2012-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
In Transmissible Spongiform Encephalopathies (TSEs) and Alzheimer disease (AD) both misfolding and aggregation of specific proteins represent key features. Recently, it was observed that PrP (c) is a mediator of a synaptic dysfunction induced by Aβ oligomers. We tested a novel γ secretase modulator (CHF5074) in a murine model of prion disease. Groups of female mice were intracerebrally or intraperitoneally infected with the mouse-adapted Rocky Mountain Laboratory prions. Two weeks prior infection, the animals were provided with a CHF5074-medicated diet (375 ppm) or a standard diet (vehicle) until they showed neurological signs and eventually died. In intracerebrally infected mice, oral administration of CHF5074 did not prolong survival of the animals. In intraperitoneally-infected mice, CHF5074-treated animals showed a median survival time of 21 days longer than vehicle-treated mice (p < 0.001). In these animals, immunohistochemistry analyses showed that deposition of PrP (Sc) in the cerebellum, hippocampus and parietal cortex in CHF5074-treated mice was significantly lower than in vehicle-treated animals. Immunostaining of glial fibrillary acidic protein (GFAP) in parietal cortex revealed a significantly higher reactive gliosis in CHF5074-treated mice compared to the control group of infected animals. Although the mechanism underlying the beneficial effects of CHF5074 in this murine model of human prion disease is unclear, it could be hypothesized that the drug counteracts PrP (Sc ) toxicity through astrocyte-mediated neuroprotection. CHF5074 shows a pharmacological potential in murine models of both AD and TSEs thus suggesting a link between these degenerative pathologies.
What this study adds
Evidence grade: Low
In mice infected with prions, the drug CHF5074 did not prolong survival when given into the brain, but did extend median survival by 21 days in mice infected in the abdomen. This is an animal study of prion disease, not Alzheimer's disease, so it does not establish any treatment or prevention benefit for people with Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Poli, G., Corda, E., Lucchini, B., Puricelli, M., Martino, P. A., Dall'ara, P., et al. (2012). Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie. Prion. https://doi.org/10.4161/pri.6.1.18317
Vancouver
Poli G, Corda E, Lucchini B, Puricelli M, Martino PA, Dall'ara P, et al. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie. Prion. 2012. doi:10.4161/pri.6.1.18317. PMID: 22453180.
BibTeX
@article{poli2012-22453180,
author = {Poli, G. and Corda, E. and Lucchini, B. and Puricelli, M. and Martino, P. A. and Dall'ara, P. and Villetti, G. and Bareggi, SR. and others},
title = {{Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie}},
journal = {Prion},
year = {2012},
doi = {10.4161/pri.6.1.18317},
pmid = {22453180},
url = {https://doi.org/10.4161/pri.6.1.18317}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In these animals, immunohistochemistry analyses showed that deposition of PrP (Sc) in the cerebellum, hippocampus and parietal cortex in CHF5074-treated mice was significantly lower than in vehicle-treated animals.
- Immunostaining of glial fibrillary acidic protein (GFAP) in parietal cortex revealed a significantly higher reactive gliosis in CHF5074-treated mice compared to the control group of infected animals.
Why it matters
In mice infected with prions, the drug CHF5074 did not prolong survival when given into the brain, but did extend median survival by 21 days in mice infected in the abdomen. This is an animal study of prion disease, not Alzheimer's disease, so it does not establish any treatment or prevention benefit for people with Alzheimer's.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Prion) |
| Journal's citation record | 0 / 4 | Prion: journal h-index 59 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Bruno Pietro Imbimbo: h-index 64 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Milan: institution h-index 1,023 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22453180) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.